Back to Dashboard
MDGL · Healthcare

MADRIGAL PHARMACEUTICALS INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Weak — few signals

No standout activity across the feeds we track.

Hedge funds
50
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Limited info. MADRIGAL PHARMACEUTICALS INC is not currently in our model portfolio, but 9 tracked investors hold it. We're showing what we know from their latest 13F filings.
Market cap
$12.8B
Industry
Biotechnology
Exchange
NasdaqGS
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
9
Investors
0
New positions
5
Increasing
4
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Alkeon Capital Management
Trust weight: 1.2×
Increased +100%
% of portfolio
0.6%
Position change
+100%
0.6% of Alkeon Capital Management's portfolio
Point72 (Steve Cohen)
Trust weight: 1.1×
Increased +207%
% of portfolio
0.1%
Position change
+207%
0.1% of Point72's portfolio
Tudor Investment (Paul Tudor Jones)
Trust weight: 1.2×
Increased +471%
% of portfolio
0.0%
Position change
+471%
0.0% of Tudor Investment's portfolio
AQR Capital Management
Trust weight: 1.0×
Increased +52%
% of portfolio
0.0%
Position change
+52%
0.0% of AQR Capital Management's portfolio
Millennium Management (Englander)
Trust weight: 1.0×
Increased +288%
% of portfolio
0.0%
Position change
+288%
0.0% of Millennium Management's portfolio
Paulson & Co (Paulson)
Trust weight: 1.2×
Decreased −10%
% of portfolio
30.5%
Position change
−10%
30.5% of Paulson & Co's portfolio
Bridgewater Associates (Dalio)
Trust weight: 1.3×
Decreased −31%
% of portfolio
0.0%
Position change
−31%
0.0% of Bridgewater Associates's portfolio
D.E. Shaw & Co
Trust weight: 1.0×
Decreased −8%
% of portfolio
0.0%
Position change
−8%
0.0% of D.E. Shaw & Co's portfolio
Citadel Advisors
Trust weight: 1.0×
Decreased −25%
% of portfolio
0.0%
Position change
−25%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to MADRIGAL PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell MADRIGAL PHARMACEUTICALS INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime
© 2026 Bogen Capital  ·  Not financial advice  ·  Data delayed up to 135 days Methodology  ·  Contact  ·  API